AMRA Medical

What AMRA Medical does

AMRA Medical is a Swedish digital health company, founded in 2010 in Linköping, that develops MRI-based body composition analysis technology for both clinical care and pharmaceutical research. Its core offering, AMRA Profiler 4, is a CE-marked (NB 2862) and FDA 510(k)-cleared (K211983) medical device that applies patented automated image analysis to classify and quantify fat and muscle groups from whole-body MRI scans in an 8–10 minute protocol. The platform is supported by a reference database of more than 55,000 fat and muscle measurements, enabling proprietary derived metrics such as weight-invariant Z-Scores and the Muscle Assessment Score (MAsS), which are validated in over 200 peer-reviewed publications.

AMRA operates a dual-track business model. For life sciences customers — pharmaceutical companies, biotechs, CROs/iCROs, and academic institutions — AMRA Researcher delivers imaging biomarkers, insights biomarkers, and scientific advisory services as part of multi-year clinical trial engagements. For clinical customers, AMRA offers the BCP Scan and MAsS Scan services through its own provision in the US, Canada, Sweden, Germany, the Netherlands, and the UK, and through channel partnerships such as Prescan in the Netherlands. The company has certified 500+ imaging sites globally to run its standardized MRI protocols, creating an embedded footprint across multi-center trials and health & wellness clinics. Pricing is quote-based, multi-year, and scoped to sites, scans, and measurement outputs, with results delivered within two business days.

The company is privately held, led by CEO Olof Dahlqvist Leinhard, with offices in Linköping, Stockholm, and Chicago. AMRA has recently expanded into three new European markets in 2025 and has stated plans for additional country rollouts in 2026, while deepening its role in neuromuscular and metabolic disease research through initiatives such as the FSHD Industry Collaborative with Sanofi, Fulcrum Therapeutics, and Scholar Rock.

Name

AMRA Medical

Legal name

AMRA Medical AB

Website

https://amramedical.com

Company type

Private

Founded year

2010

Operating status

Operating

Headcount range

11–50 employees

Short description

AMRA Medical is a Swedish digital health company that provides MRI-based body composition analysis for pharmaceutical clinical trials, academic research, and preventive health clinics. Its proprietary Profiler 4 platform delivers fat and muscle biomarkers across 500+ certified imaging sites globally.

Ownership category

akta.pro rank

Product category

Medical Imaging Analytics Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Laboratories (621511), Scientific Research and Development Services (5417), Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (33451)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industries

Medical Imaging AI (HDAAAEAH), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM), Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry) (HLAGAEAB)

Keywords

• MRI body composition analysis
• Medical imaging biomarkers
• Digital health platform
• Clinical trial imaging
• Fat muscle quantification

Headquarters

HQ city

Linköping

HQ country

Sweden

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure, Others

Revenue model

1. Clinical Services - AMRA BCP Scan: MRI-based body composition scanning service for health and wellness clinics. Cost is dependent upon number of sites, scans, measurements, and delivery outputs. Results delivered within 2 business days (24-hour expedited available).
2. Research Services - Clinical Trials: MRI biomarker services for pharmaceutical companies, biotechs, CROs/iCROs, and academic institutions supporting drug development. Services include imaging biomarkers, insights biomarkers, and scientific advisory services for clinical trial design and execution.
3. Site Certification and Protocol Services: Certification of imaging sites with AMRA's MRI protocols. Over 500 imaging sites globally certified with the AMRA imaging protocol.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels9 records

Core offering

AMRA Medical develops and operates a cloud-based digital health platform that uses patented automated MRI image analysis to classify and quantify fat and muscle tissue, marketed through its FDA 510(k)-cleared and CE-marked medical device software, AMRA Profiler 4. The company sells clinical scanning services (AMRA BCP Scan, AMRA MAsS Scan) to health and wellness centers and research services (AMRA Researcher, Imaging Biomarkers, Insights Biomarkers, Scientific Advisory Services) to pharmaceutical, biotech, CRO, and academic customers supporting drug development and clinical trials.

Product overview

AMRA Medical offers a unified platform combining proprietary MRI-based body composition analysis technology with cloud-based digital health services. The core offering centers on AMRA® Profiler 4, a regulated medical device (CE-marked NB 2862, FDA 510(k)-cleared K211983), which powers two clinical service products: AMRA® BCP Scan for comprehensive body composition profiling and AMRA® MAsS Scan for muscle quality assessment. For research applications, AMRA® Researcher provides a digital health platform delivering Imaging Biomarkers (fat and muscle measurements from MRI) and Insights Biomarkers (derived Z-Scores, MAsS, and Composite Scores). Scientific Advisory Services complement the platform with expert consultation. The technology uses patented automated methods for classifying and quantifying fat and muscle groups from MRI scans, supported by a reference database of over 55,000 measurements.

Differentiator

Problem solved

Functional benefit

Brands

• AMRA® BCP Scan: MRI-based body composition profile scan service providing fat distribution and muscle composition measurements.
• AMRA® MAsS Scan
• AMRA® Profiler 4
• AMRA® Researcher
• AMRA® Z-Scores

Products and services

• AMRA Profiler 4 AMRA Profiler 4 is a 510(k)-cleared (K211983) and CE-marked (NB 2862) medical device software application for non-invasive fat and muscle evaluation. It generates, displays, and reviews 2D MR medical image data for clinical diagnosis, producing easy-to-understand, individualized body composition insights for each patient profile.
• AMRA BCP Scan AMRA BCP Scan is a neck-to-knee MRI-based clinical service that creates an individualized Body Composition Profile (BCP), measuring visceral fat, subcutaneous fat, muscle fat, muscle volume, and liver fat with comparison to a normative reference database. It is offered to health and wellness clinics and patients for preventive health risk assessment.
• AMRA MAsS Scan AMRA MAsS Scan is a clinical muscle assessment service providing an actionable, easy-to-understand muscle quality score based on MRI measurements of muscle size and fat content, contextualized against patient-specific virtual control groups. It is intended for clinicians and patients focused on muscle health evaluation.
• AMRA Researcher AMRA Researcher is a digital health platform that provides full-stack MRI analysis support for multi-center clinical trials and research studies. It powers research services with a wide array of fat and muscle biomarkers, enabling streamlined workflows and standardized body composition analysis for drug development customers.
• Scientific Advisory Services End-to-end clinical research support offering including biomarker selection and implementation, clinical protocol design, exploratory biomarker discovery, and expert data analytics to maximize R&D success for pharmaceutical, biotech, CRO, and academic customers.
• Site Certification and Protocol Services Certification of imaging sites with AMRA's MRI protocols, with over 500 imaging sites globally certified to deliver standardized AMRA body composition scans as part of clinical trial and clinical service operations.

Quantifiable outcome

• 55,000+ reference measurements enabling normative comparisons
• +4 more outcomes

Named customers4 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability4 records

Feature8 records

Partnerships

Seven partnerships are on record, tiered flagship and core.

• SanofiflagshipGTM or Marketing Partner · 8 April 2026Key sponsor of the FSHD Industry Collaborative, a multi-stakeholder initiative launched by The FSHD Society, SOLVE FSHD, and the FSHD Clinical Trial Research Network. The collaborative brings together biopharma companies, academic experts, and technology partners including AMRA to improve facioscapulohumeral muscular dystrophy clinical trials.
• Fulcrum TherapeuticsflagshipGTM or Marketing Partner · 8 April 2026Key sponsor of the FSHD Industry Collaborative, a multi-stakeholder initiative to improve facioscapulohumeral muscular dystrophy clinical trials. The collaborative analyzes biomarker and clinical data to reduce drug development risk and support unified regulatory narratives.
• Scholar RockflagshipGTM or Marketing Partner · 8 April 2026Key sponsor of the FSHD Industry Collaborative, a multi-stakeholder initiative to improve facioscapulohumeral muscular dystrophy clinical trials. The collaborative brings together biopharma companies, academic experts, and technology partners including AMRA to analyze biomarker and clinical data.
• FSHD SocietyflagshipStrategic or Co-development Partner · 8 April 2026Launched the FSHD Industry Collaborative along with SOLVE FSHD and the FSHD Clinical Trial Research Network to improve how facioscapulohumeral muscular dystrophy clinical trials are designed, executed, and evaluated.
• SOLVE FSHDflagshipStrategic or Co-development Partner · 8 April 2026Co-founded the FSHD Industry Collaborative with The FSHD Society and the FSHD Clinical Trial Research Network to improve facioscapulohumeral muscular dystrophy clinical trials through multi-stakeholder collaboration.
• FSHD Clinical Trial Research NetworkflagshipStrategic or Co-development Partner · 8 April 2026Co-founded the FSHD Industry Collaborative with The FSHD Society and SOLVE FSHD to improve facioscapulohumeral muscular dystrophy clinical trials through multi-stakeholder collaboration involving biopharma companies, academic experts, and technology partners.
• PrescancoreChannel Partner/ Reseller/ Distributor · 8 January 2026Strategic partnership with Dutch preventative healthcare leader Prescan to launch AMRA BCP Scan service in the Netherlands. Prescan is an independent health & wellness clinic in Baarn specializing in preventive health screenings. The partnership marks BCP Scan's third European market entry in 2025 (after Sweden and Germany) and makes Prescan the only center offering BCP Scan in the Netherlands.

Scale indicators6 records

Recent moves4 records

Expansion highlights6 records

Direct peers

• Median Technologies: Median Technologies provides imaging AI and biomarker analysis for oncology and metabolic clinical trials, including lesion-level and organ-level quantification for sponsors. Like AMRA, it sells an imaging biomarker platform to pharma/biotech for trial endpoint and patient stratification use cases.
• Quibim: Quibim offers an AI-powered medical imaging biomarker platform that extracts quantitative features from MRI and CT scans for research and clinical use, including in metabolic and musculoskeletal disease. Its positioning as a multi-organ imaging biomarker vendor for clinical research directly mirrors AMRA's value proposition.
• Epsilon Imaging: Epsilon Imaging provides post-processing and quantification software for medical imaging, with a strong focus on cardiac and specialty imaging workflows used in clinical research and practice. Its imaging analytics software model for specialty clinical use cases is structurally similar to AMRA's Profiler 4 / Researcher platform.
• HealthMyne: HealthMyne delivers imaging analytics and AI-driven quantification for radiology and oncology workflows, enabling structured measurements from imaging studies for clinical and research applications. It is comparable to AMRA as a quantitative imaging analytics platform sold to clinical and research customers.
• Perspectum: Perspectum develops MRI-based diagnostic and biomarker products for metabolic and liver disease (e.g., LiverMultiScan), serving both clinical practice and pharma-sponsored clinical trials. It is the closest direct competitor to AMRA in using quantitative MRI imaging biomarkers for clinical research and care, particularly in MASLD and metabolic indications.

Broad incumbents

• Philips: Philips is a large incumbent in medical imaging equipment, PACS, and AI-enabled clinical informatics, with broad exposure to MRI and AI-driven clinical decision support. As a broad incumbent, it could bundle body composition analytics alongside its MRI and radiology IT offerings, posing a competitive threat to AMRA's specialty niche.
• GE HealthCare: GE HealthCare is a major medical imaging equipment and digital health incumbent with significant MRI and imaging AI capabilities. It is a relevant comparable as a broad incumbent whose imaging platform investments and AI offerings could overlap with AMRA's clinical and research biomarker services over time.
• Siemens Healthineers: Siemens Healthineers is a global medical imaging and diagnostics incumbent with a large MRI installed base and growing AI imaging applications. Its broad portfolio and customer relationships across hospital systems and CROs position it as a potential platform-level competitor to AMRA's specialty imaging biomarkers.

Emerging players

• Arterys: Arterys (now part of Tempus) provides a cloud-native AI platform for medical imaging analysis across multiple modalities, including body composition and oncology imaging. It overlaps with AMRA in the cloud-based medical imaging AI space and serves similar clinical and research customers, though with a broader, less specialty-focused portfolio.

Others

• Calyx: Calyx provides AI-enabled medical imaging solutions and clinical trial technology for the life sciences industry, including imaging management and review for clinical trials. It is adjacent to AMRA as an enabling technology partner serving pharma-sponsored trials, with partial overlap in the clinical trial imaging workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/AMRAMedical
• Facebookfacebook.com/AMRAMEDICAL
• LinkedInlinkedin.com/company/amra-ab

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AMRA Medical